Predictors of Impaired Daytime Sleep and Wakefulness in Patients with Parkinson Disease Treated with Older (Ergot) vs Newer (Nonergot) Dopamine Agonists

Archives of Neurology

Volumn 61, Issue 1, 2004, Pages 97-102

  Razmy, Ajmal ^a   Lang, Anthony E ^b   Shapiro, Colin M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE MESILATE; CARBIDOPA PLUS LEVODOPA; CLONAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT ALKALOID; LEVODOPA; PERGOLIDE MESILATE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TOLCAPONE;

ADULT; AGED; ARTICLE; CANADA; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POLYSOMNOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SLOW WAVE SLEEP; SOMNOLENCE; VISUAL ANALOG SCALE; WAKEFULNESS;

AGED; BENZOTHIAZOLES; BROMOCRIPTINE; DISORDERS OF EXCESSIVE SOMNOLENCE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOT ALKALOIDS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PARKINSON DISEASE; PERGOLIDE; POLYSOMNOGRAPHY; PROSPECTIVE STUDIES; SLEEP; THIAZOLES; WAKEFULNESS;

EID: 0346057961     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.1.97     Document Type: Article

References (35)

1. Hobson DE, Pourcher E, Martin WR. Ropinirole and pramipexole, the new agonists. Can J Neurol Sci. 1999;26(suppl 2):S27-S33.
2. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-1491.
3. Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol. 1998;44(suppl 1):S167-S174.
4. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908-1910.
5. Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials. Drug Saf. 2001;24:863-868.
6. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord. 2000;15:658-663.
7. Paladini D. Sleep attacks in two Parkinson's disease patients taking ropinirole [abstract]. Mov Disord. 2000;15(suppl 3):130-131.
8. Ryan M, Slevin JT, Wells A. Non-ergot dopamine agonist-induced sleep attacks. Pharmacotherapy. 2000;20:724-726.
9. Montastruc JL, Brefel-Courbon C, Senard JM, et al. Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol 2001;24:181-183.
10. Ondo WG, Dat VK, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001;57:1392-1396.
11. Pal S, Bhattacharya KF, Agapito C, Chaudhuri KR. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm. 2001;108:71-77.
12. Tracik F, Ebersbach G. Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings. Mov Disord. 2001;16:500-506.
13. Ferreira JJ, Galitzky M, Brefel-Courbon C, et al. "Sleep attacks" as an adverse drug reaction of levodopa monotherapy [abstract]. Mov Disord. 2000;15(suppl 3):129.
14. Schapira AH. Sleep attacks (sleep episodes) with pergolide. Lancet. 2000;355:1332-1333.
15. Olanow CW, Schapira AH, Roth T. Waking up to sleep episodes in Parkinson's disease. Mov Disord. 2000;15:212-215.
16. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14:540-545.
17. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. 1992;15:376-381.
18. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
19. Gillingham FJ, Donaldson MC, eds. Schwab and England Activities of Daily Living. New York, NY: Churchill Livingstone Inc; 1969.
20. Hobson DE, Lang AE, Martin WRW, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden sleep onset in Parkinson's disease: a survey by the Canadian Movement Disorders Group. JAMA. 2002;287:455-463.
21. Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. 1968. Washington, DC: US Public Health Service; 1968.
22. Agnew HW Jr, Webb WB, Williams RL. The first night effect: an EEG study of sleep. Psychophysiology. 1966;2:263-266.
23. Carskadon MA, Dement WC. The multiple sleep latency test: what does it measure? Sleep. 1982;5(suppl 2):S67-S72.
24. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbook PR, Keenan S. Guidelines for the Multiple Sleep Latency Test (MSLT): a standard measure of sleepiness. Sleep. 1986;9:519-524.
25. Mitler MM, Gujavarty KS, Browman CP. Maintenance of wakefulness test: a polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence. Electroencephalogr Clin Neurophysiol. 1982;53:658-661.
26. Mitler MM, Doghramji K, Shapiro C. The maintenance of wakefulness test: normative data by age. J Psychosom Res. 2000;49:363-365.
27. Akerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci. 1990;52:29-37.
28. Hosmer DW, Lemeshow S, Saulnier F. Applied Logistic Regression. New York, NY: John Wiley & Sons Inc; 1989.
29. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
30. Lagos P, Scorza C, Monti JM, et al. Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats. Eur Neuropsychopharmacol. 1998;8:113-120.
31. Tracik F, Ebersbach G. Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings. Mov Disord. 2001;16:500-506.
32. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908-1910.
33. Merino-Andreu M, Arnuf I, Konofal E, Derenne JP, Agid Y. Unawareness of naps in Parkinson's disease and in disorders with excessive daytime sleepiness. Neurology. 2003;60:1553-1554.
34. Jellinger K. Pathology of parkinsonism. In: Fahn S, Marsden CD, Jenner P, et al, eds. Recent Developments in Parkinson's Disease. New York, NY: Raven Press; 1986:33-66.
35. Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL. The pedunculopontine nucleus in Parkinson's disease. Ann Neurol. 1989;26:41-46.